IOL Chemicals and Pharmaceuticals Limited has made available the audio recording of its business update conference call with investors and analysts. The session was held on Friday, September 11, 2026.

The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the National Stock Exchange of India Ltd and BSE Limited regarding the availability of the recording.

Call Details

The audio file is hosted on the company’s official website. Investors and analysts can access the recording via the link provided in the exchange filing. Abhay Raj Singh, Senior Vice President and Company Secretary, signed the communication on behalf of the board.

Regulatory Compliance

The filing serves as a mandatory regulatory update under SEBI norms. It ensures transparency by providing market participants with direct access to management commentary from the recent investor interaction.

IOL Chemicals & Pharmaceuticals has announced a comprehensive expansion plan valued at approximately ₹495 crore, covering new ibuprofen capacity, a contract development and manufacturing organisation (CDMO) facility, and a dedicated specialty chemicals unit.

The initiatives, disclosed on September 9, 2026, aim to strengthen the company's manufacturing capabilities and broaden its product portfolio. All projects are proposed to be funded through internal accruals.

Ibuprofen capacity expansion

The company is setting up a fully backward-integrated manufacturing unit for ibuprofen at its existing site in Barnala, Punjab. The new facility will add 6,000 MTPA of capacity, increasing the total installed capacity from 12,000 MTPA to 18,000 MTPA upon commissioning.

The expansion addresses growing global demand for ibuprofen and leverages the company's existing customer base. Current capacity utilization stands at 95%.

New CDMO facility

IOL Chemicals has installed a pharmaceutical formulation manufacturing facility in Barnala, diversifying into Contract Development and Manufacturing Organisation (CDMO) services. The facility has an installed capacity of approximately 1,500 million tablets per annum or equivalent volume of Direct Compressible Grade.

Key details include:

• Project cost: Approximately ₹110 crore
• Target market: Anchor customers in the European region
• Regulatory status: Received GMP Certificate from Hungary's National Centre for Public Health and Pharmacy
• Expected commercialization: Q3 FY27

This initiative is designed to cater to long-term contract manufacturing requirements, leveraging the company's regulatory compliance and technical expertise.

Specialty chemicals unit

The company is establishing a dedicated manufacturing facility for a specialty chemical product under a long-term tolling arrangement with a leading global chemical company. The project involves an estimated capital expenditure of approximately ₹35 crore.

The facility will manufacture and supply the product exclusively for the customer. Commercial supplies are expected to commence during Q3 FY27. The arrangement is projected to contribute materially to the company's revenue stream.

What the Numbers Show

The total investment of ₹495 crore represents a significant commitment to capacity expansion, with the ibuprofen plant accounting for roughly 71% of the total capital outlay (₹350 crore out of ₹495 crore). This concentration underscores ibuprofen as the primary growth driver, while the smaller investments in CDMO and specialty chemicals signal a strategic push into higher-value, service-oriented segments to diversify revenue streams beyond pure API manufacturing.